{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:07:06Z","timestamp":1784128026823,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>ETV4 is one of the ETS proteins overexpressed in prostate cancer (PC) as a result of recurrent chromosomal translocations. In human prostate cell lines, ETV4 promotes migration, invasion, and proliferation; however, its role in PC has been unclear. In this study, we have explored the effects of ETV4 expression in the prostate in a novel transgenic mouse model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We have created a mouse model with prostate-specific expression of ETV4 (ETV4 mice). By histochemical and molecular analysis, we have investigated in these engineered mice the expression of p21, p27, and p53. The implications of our in vivo findings have been further investigated in human cells lines by chromatin-immunoprecipitation (ChIP) and luciferase assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ETV4 mice, from two independent transgenic lines, have increased cell proliferation in their prostate and two-thirds of them, by the age of 10 months, developed mouse prostatic intraepithelial neoplasia (mPIN). In these mice,<jats:italic>cdkn1a<\/jats:italic>and its p21 protein product were reduced compared to controls; p27 protein was also reduced. By ChIP assay in human prostate cell lines, we show that ETV4 binds to a specific site (-704\/-696 bp upstream of the transcription start) in the<jats:italic>CDKN1A<\/jats:italic>promoter that was proven, by luciferase assay, to be functionally competent. ETV4 further controls<jats:italic>CDKN1A<\/jats:italic>expression by downregulating p53 protein: this reduction of p53 was confirmed in vivo in ETV4 mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ETV4 overexpression results in the development of mPIN but not in progression to cancer. ETV4 increases prostate cell proliferation through multiple mechanisms, including downregulation of<jats:italic>CDKN1A<\/jats:italic>and its p21 protein product: this in turn is mediated through direct binding of ETV4 to the<jats:italic>CDKN1A<\/jats:italic>promoter and through the ETV4-mediated decrease of p53. This multi-faceted role of ETV4 in prostate cancer makes it a potential target for novel therapeutic approaches that could be explored in this ETV4 transgenic model.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13045-020-00943-w","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T13:03:48Z","timestamp":1597323828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21"],"prefix":"10.1186","volume":"13","author":[{"given":"Irene","family":"Cosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Pellecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Nesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Notaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-6457","authenticated-orcid":false,"given":"Maria","family":"De Angioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"issue":"1","key":"943_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin."},{"issue":"27","key":"943_CR2","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2011.35.1916","volume":"29","author":"MA Rubin","year":"2011","unstructured":"Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27):3659\u201368.","journal-title":"J Clin Oncol."},{"key":"943_CR3","doi-asserted-by":"crossref","unstructured":"Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, Henrique R, et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer. 2012;51(3):240\u20139.","DOI":"10.1002\/gcc.20948"},{"issue":"8","key":"943_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11912-018-0707-9","volume":"20","author":"K Arora","year":"2018","unstructured":"Arora K, Barbieri CE. Molecular subtypes of prostate cancer. Curr Oncol Rep. 2018;20(8):58.","journal-title":"Curr Oncol Rep."},{"key":"943_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-030-32656-2_18","volume":"1210","author":"TR Nicholas","year":"2019","unstructured":"Nicholas TR, Strittmatter BG, Hollenhorst PC. Oncogenic ETS factors in prostate cancer. Adv Exp Med Biol. 2019;1210:409\u201336.","journal-title":"Adv Exp Med Biol."},{"issue":"10","key":"943_CR6","first-page":"2079","volume":"9","author":"C Yu","year":"2019","unstructured":"Yu C, Hu K, Nguyen D, Wang ZA. From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer. Am J Cancer Res. 2019;9(10):2079\u2013102.","journal-title":"Am J Cancer Res."},{"issue":"2","key":"943_CR7","doi-asserted-by":"crossref","first-page":"a030528","DOI":"10.1101\/cshperspect.a030528","volume":"9","author":"JM Arriaga","year":"2019","unstructured":"Arriaga JM, Abate-Shen C. Genetically engineered mouse models of prostate cancer in the postgenomic era. Cold Spring Harb Perspect Med. 2019;9(2):a030528.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"7153","key":"943_CR8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","volume":"448","author":"SA Tomlins","year":"2007","unstructured":"Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448(7153):595\u20139.","journal-title":"Nature."},{"issue":"6","key":"943_CR9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1073\/pnas.0711711105","volume":"105","author":"O Klezovitch","year":"2008","unstructured":"Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008;105(6):2105\u201310.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"943_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1593\/neo.07822","volume":"10","author":"SA Tomlins","year":"2008","unstructured":"Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10(2):177\u201388.","journal-title":"Neoplasia."},{"issue":"30","key":"943_CR11","doi-asserted-by":"crossref","first-page":"12465","DOI":"10.1073\/pnas.0905931106","volume":"106","author":"Y Zong","year":"2009","unstructured":"Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A. 2009;106(30):12465\u201370.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"20","key":"943_CR12","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1158\/0008-5472.CAN-09-0941","volume":"69","author":"S Shin","year":"2009","unstructured":"Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, et al. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1\/ETS-related protein 81. Cancer Res. 2009;69(20):8102\u201310.","journal-title":"Cancer Res."},{"issue":"7231","key":"943_CR13","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature07738","volume":"457","author":"BS Carver","year":"2009","unstructured":"Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, et al. ETS rearrangements and prostate cancer initiation. Nature. 2009;457(7231):E1 discussion E2-3.","journal-title":"Nature"},{"issue":"5","key":"943_CR14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","volume":"41","author":"BS Carver","year":"2009","unstructured":"Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41(5):619\u201324.","journal-title":"Nat Genet."},{"issue":"5","key":"943_CR15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","volume":"41","author":"JC King","year":"2009","unstructured":"King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5):524\u20136.","journal-title":"Nat Genet."},{"issue":"7","key":"943_CR16","doi-asserted-by":"crossref","first-page":"e41668","DOI":"10.1371\/journal.pone.0041668","volume":"7","author":"OM Casey","year":"2012","unstructured":"Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, et al. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One. 2012;7(7):e41668.","journal-title":"PLoS One."},{"issue":"6","key":"943_CR17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1101\/gad.211011.112","volume":"27","author":"E Baena","year":"2013","unstructured":"Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013;27(6):683\u201398.","journal-title":"Genes Dev."},{"issue":"8","key":"943_CR18","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.3216","volume":"19","author":"Y Chen","year":"2013","unstructured":"Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013;19(8):1023\u20139.","journal-title":"Nat Med."},{"issue":"6","key":"943_CR19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0964-1955(97)00047-X","volume":"33","author":"K Hida","year":"1997","unstructured":"Hida K, Shindoh M, Yoshida K, Kudoh A, Furaoka K, Kohgo T, et al. Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol. 1997;33(6):426\u201330.","journal-title":"Oral Oncol."},{"issue":"13","key":"943_CR20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.onc.1201331","volume":"15","author":"CC Benz","year":"1997","unstructured":"Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, et al. HER2\/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene. 1997;15(13):1513\u201325.","journal-title":"Oncogene."},{"key":"943_CR21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/0-306-46832-8_13","volume":"480","author":"Y de Launoit","year":"2000","unstructured":"de Launoit Y, Chotteau-Lelievre A, Beaudoin C, Coutte L, Netzer S, Brenner C, et al. The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol. 2000;480:107\u201316.","journal-title":"Adv Exp Med Biol."},{"issue":"6","key":"943_CR22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.1410","volume":"93","author":"H Hiroumi","year":"2001","unstructured":"Hiroumi H, Dosaka-Akita H, Yoshida K, Shindoh M, Ohbuchi T, Fujinaga K, et al. Expression of E1AF\/PEA3, an Ets-related transcription factor in human non-small-cell lung cancers: its relevance in cell motility and invasion. Int J Cancer. 2001;93(6):786\u201391.","journal-title":"Int J Cancer."},{"issue":"1","key":"943_CR23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbrc.2006.04.094","volume":"345","author":"AC Moss","year":"2006","unstructured":"Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, et al. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem Biophys Res Commun. 2006;345(1):216\u201321.","journal-title":"Biochem Biophys Res Commun."},{"issue":"16","key":"943_CR24","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1158\/0008-5472.CAN-05-2902","volume":"66","author":"S Upadhyay","year":"2006","unstructured":"Upadhyay S, Liu C, Chatterjee A, Hoque MO, Kim MS, Engles J, et al. LKB1\/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Res. 2006;66(16):7870\u20139.","journal-title":"Cancer Res."},{"issue":"7","key":"943_CR25","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/0008-5472.CAN-06-0168","volume":"66","author":"SA Tomlins","year":"2006","unstructured":"Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66(7):3396\u2013400.","journal-title":"Cancer Res."},{"issue":"18","key":"943_CR26","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1158\/0008-5472.CAN-08-2014","volume":"68","author":"B Han","year":"2008","unstructured":"Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68(18):7629\u201337.","journal-title":"Cancer Res."},{"issue":"9","key":"943_CR27","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/0008-5472.CAN-08-0198","volume":"68","author":"KG Hermans","year":"2008","unstructured":"Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008;68(9):3094\u20138.","journal-title":"Cancer Res."},{"issue":"21","key":"943_CR28","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1158\/0008-5472.CAN-06-1986","volume":"66","author":"K Iljin","year":"2006","unstructured":"Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66(21):10242\u20136.","journal-title":"Cancer Res."},{"key":"943_CR29","doi-asserted-by":"crossref","unstructured":"Dedigama-Arachchige P, Carskadon S, Li J, Loveless I, Alhamar M, Peabody JO, et al. Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. Mod Pathol. 2020. Online ahead of print.","DOI":"10.1101\/818880"},{"issue":"7","key":"943_CR30","first-page":"1461","volume":"10","author":"F Higashino","year":"1995","unstructured":"Higashino F, Yoshida K, Noumi T, Seiki M, Fujinaga K. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene. 1995;10(7):1461\u20133.","journal-title":"Oncogene."},{"issue":"5","key":"943_CR31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/path.1387","volume":"200","author":"S Horiuchi","year":"2003","unstructured":"Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol. 2003;200(5):568\u201376.","journal-title":"J Pathol."},{"issue":"1","key":"943_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.07.020","volume":"216","author":"M Shindoh","year":"2004","unstructured":"Shindoh M, Higashino F, Kohgo T. E1AF, an ets-oncogene family transcription factor. Cancer Lett. 2004;216(1):1\u20138.","journal-title":"Cancer Lett."},{"issue":"10","key":"943_CR33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/1947601910395578","volume":"1","author":"PC Hollenhorst","year":"2011","unstructured":"Hollenhorst PC, Paul L, Ferris MW, Graves BJ. The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer. 2011;1(10):1044\u201352.","journal-title":"Genes Cancer."},{"key":"943_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2012.20","volume":"1","author":"A Pellecchia","year":"2012","unstructured":"Pellecchia A, Pescucci C, De Lorenzo E, Luceri C, Passaro N, Sica M, et al. Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis. 2012;1:e20.","journal-title":"Oncogenesis."},{"issue":"2","key":"943_CR35","first-page":"211","volume":"11","author":"X Grana","year":"1995","unstructured":"Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11(2):211\u20139.","journal-title":"Oncogene."},{"issue":"4","key":"943_CR36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","volume":"8","author":"IM Chu","year":"2008","unstructured":"Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253\u201367.","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"943_CR37","first-page":"324","volume":"11","author":"JC Cheville","year":"1998","unstructured":"Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol. 1998;11(4):324\u20138.","journal-title":"Mod Pathol."},{"issue":"7","key":"943_CR38","first-page":"2613","volume":"9","author":"M Drobnjak","year":"2003","unstructured":"Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res. 2003;9(7):2613\u20139.","journal-title":"Clin Cancer Res."},{"issue":"7","key":"943_CR39","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/1097-0142(20011001)92:7<1828::AID-CNCR1699>3.0.CO;2-Q","volume":"92","author":"H Noda","year":"2001","unstructured":"Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K. Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1\/CIP1 in early gastric carcinoma. Cancer. 2001;92(7):1828\u201335.","journal-title":"Cancer."},{"issue":"18","key":"943_CR40","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2002.09.147","volume":"20","author":"T Shoji","year":"2002","unstructured":"Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol. 2002;20(18):3865\u201371.","journal-title":"J Clin Oncol."},{"issue":"6","key":"943_CR41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.2004.03.118","volume":"22","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014\u201324.","journal-title":"J Clin Oncol."},{"issue":"1","key":"943_CR42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbrc.2007.04.043","volume":"358","author":"J Jiang","year":"2007","unstructured":"Jiang J, Wei Y, Liu D, Zhou J, Shen J, Chen X, et al. E1AF promotes breast cancer cell cycle progression via upregulation of Cyclin D3 transcription. Biochem Biophys Res Commun. 2007;358(1):53\u20138.","journal-title":"Biochem Biophys Res Commun."},{"issue":"11","key":"943_CR43","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdn402","volume":"19","author":"G Somlo","year":"2008","unstructured":"Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow JH, et al. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol. 2008;19(11):1853\u20139.","journal-title":"Ann Oncol."},{"issue":"8","key":"943_CR44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0046-8177(98)90445-2","volume":"29","author":"H Matsushima","year":"1998","unstructured":"Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T, et al. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol. 1998;29(8):778\u201383.","journal-title":"Hum Pathol."},{"issue":"5","key":"943_CR45","first-page":"1896","volume":"6","author":"L Cheng","year":"2000","unstructured":"Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6(5):1896\u20139.","journal-title":"Clin Cancer Res."},{"issue":"32","key":"943_CR46","doi-asserted-by":"crossref","first-page":"24500","DOI":"10.1074\/jbc.M003145200","volume":"275","author":"JR Graff","year":"2000","unstructured":"Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 2000;275(32):24500\u20135.","journal-title":"J Biol Chem."},{"issue":"11","key":"943_CR47","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1210\/endo.142.11.8467","volume":"142","author":"H Murillo","year":"2001","unstructured":"Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001;142(11):4795\u2013805.","journal-title":"Endocrinology."},{"issue":"3","key":"943_CR48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1097-0215(20010520)95:3<135::AID-IJC1023>3.0.CO;2-3","volume":"95","author":"L Lacombe","year":"2001","unstructured":"Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer. 2001;95(3):135\u20139.","journal-title":"Int J Cancer."},{"issue":"3","key":"943_CR49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pros.1134","volume":"49","author":"EA Omar","year":"2001","unstructured":"Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate. 2001;49(3):191\u20139.","journal-title":"Prostate."},{"issue":"4","key":"943_CR50","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"TCGAR Network","year":"2015","unstructured":"Network TCGAR. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011\u201325.","journal-title":"Cell."},{"issue":"12","key":"943_CR51","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1210\/endo.141.12.7837","volume":"141","author":"J Zhang","year":"2000","unstructured":"Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology. 2000;141(12):4698\u2013710.","journal-title":"Endocrinology."},{"issue":"6","key":"943_CR52","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-03-0946","volume":"64","author":"SB Shappell","year":"2004","unstructured":"Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004;64(6):2270\u2013305.","journal-title":"Cancer Res."},{"issue":"9","key":"943_CR53","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1158\/0008-5472.CAN-12-4213","volume":"73","author":"M Ittmann","year":"2013","unstructured":"Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73(9):2718\u201336.","journal-title":"Cancer Res."},{"issue":"7","key":"943_CR54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods."},{"issue":"13","key":"943_CR55","first-page":"2910","volume":"55","author":"WS el-Deiry","year":"1995","unstructured":"el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, et al. Topological control of p21WAF1\/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995;55(13):2910\u20139.","journal-title":"Cancer Res."},{"issue":"1-2","key":"943_CR56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"X Wu","year":"2001","unstructured":"Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101(1-2):61\u20139.","journal-title":"Mech Dev."},{"issue":"2","key":"943_CR57","first-page":"221","volume":"12","author":"M Kaya","year":"1996","unstructured":"Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S, Fujinaga K. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene. 1996;12(2):221\u20137.","journal-title":"Oncogene."},{"issue":"2","key":"943_CR58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.devcel.2008.01.013","volume":"14","author":"A Besson","year":"2008","unstructured":"Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14(2):159\u201369.","journal-title":"Dev Cell."},{"issue":"7","key":"943_CR59","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.18632\/oncotarget.2847","volume":"6","author":"D Mesquita","year":"2015","unstructured":"Mesquita D, Barros-Silva JD, Santos J, Skotheim RI, Lothe RA, Paulo P, et al. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget. 2015;6(7):5217\u201336.","journal-title":"Oncotarget."},{"issue":"5","key":"943_CR60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4161\/oxim.3.5.13108","volume":"3","author":"EA Ratovitski","year":"2010","unstructured":"Ratovitski EA. LKB1\/PEA3\/DeltaNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxid Med Cell Longev. 2010;3(5):317\u201324.","journal-title":"Oxid Med Cell Longev."},{"issue":"29","key":"943_CR61","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/onc.2014.308","volume":"34","author":"Z Mounir","year":"2014","unstructured":"Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2014;34(29):3815\u201325.","journal-title":"Oncogene."},{"issue":"2","key":"943_CR62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/72294","volume":"6","author":"X Xing","year":"2000","unstructured":"Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, et al. The ets protein PEA3 suppresses HER-2\/neu overexpression and inhibits tumorigenesis. Nat Med. 2000;6(2):189\u201395.","journal-title":"Nat Med."},{"issue":"1-3","key":"943_CR63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-5793(04)00104-8","volume":"560","author":"MT Discenza","year":"2004","unstructured":"Discenza MT, Vaz D, Hassell JA, Pelletier J. Activation of the WT1 tumor suppressor gene promoter by Pea3. FEBS Lett. 2004;560(1-3):183\u201391.","journal-title":"FEBS Lett."},{"issue":"12","key":"943_CR64","doi-asserted-by":"crossref","first-page":"11281","DOI":"10.1074\/jbc.M311887200","volume":"279","author":"CK Galang","year":"2004","unstructured":"Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem. 2004;279(12):11281\u201392.","journal-title":"J Biol Chem."},{"issue":"3","key":"943_CR65","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr2900","volume":"13","author":"AG Clementz","year":"2011","unstructured":"Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res. 2011;13(3):R63.","journal-title":"Breast Cancer Res."},{"issue":"9","key":"943_CR66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/mc.20212","volume":"45","author":"Z Yu","year":"2006","unstructured":"Yu Z, Xia W, Wang HY, Wang SC, Pan Y, Kwong KY, et al. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog. 2006;45(9):667\u201375.","journal-title":"Mol Carcinog."},{"issue":"3","key":"943_CR67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006639214618","volume":"17","author":"U Benbow","year":"1999","unstructured":"Benbow U, Schoenermark MP, Orndorff KA, Givan AL, Brinckerhoff CE. Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid. Clin Exp Metastasis. 1999;17(3):231\u20138.","journal-title":"Clin Exp Metastasis."},{"issue":"1","key":"943_CR68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1997.6909","volume":"236","author":"K Funaoka","year":"1997","unstructured":"Funaoka K, Shindoh M, Yoshida K, Hanzawa M, Hida K, Nishikata S, et al. Activation of the p21(Waf1\/Cip1) promoter by the ets oncogene family transcription factor E1AF. Biochem Biophys Res Commun. 1997;236(1):79\u201382.","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"943_CR69","first-page":"1","volume":"1826","author":"S Oh","year":"2012","unstructured":"Oh S, Shin S, Janknecht R. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta. 2012;1826(1):1\u201312.","journal-title":"Biochim Biophys Acta."},{"issue":"55","key":"943_CR70","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1038\/sj.onc.1204035","volume":"19","author":"R Li","year":"2000","unstructured":"Li R, Pei H, Watson DK. Regulation of Ets function by protein - protein interactions. Oncogene. 2000;19(55):6514\u201323.","journal-title":"Oncogene."},{"issue":"37","key":"943_CR71","doi-asserted-by":"crossref","first-page":"E3506","DOI":"10.1073\/pnas.1303558110","volume":"110","author":"A Aytes","year":"2013","unstructured":"Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A. 2013;110(37):E3506\u201315.","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00943-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00943-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00943-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T20:55:16Z","timestamp":1667768116000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00943-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00943-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was performed in compliance with relevant regulatory standards, and it was approved by the Institutional Animal Care and Use of University of Florence, Italy, and by the Italian Ministry of Health (issued on 2010).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest and any commercial affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}